12K(top 3%)
articles
465.3K(top 2%)
citations
3,023(top 3%)
★★ articles
80(top 3%)
★★★ articles
3.3(top 10%)
Avg IF
240(top 2%)
H-Index
389(top 2%)
G-Index
1,966
journals

Most Cited Articles of AstraZeneca in 2016

TitleJournalYearCitations
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet, The2016738
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialLancet, The2016733
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 DiabetesCell Metabolism2016730
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?Journal of Medicinal Chemistry2016726
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung CancerJournal of Clinical Oncology2016605
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite InstabilityImmunity2016602
Alternatives to antibiotics-a pipeline portfolio reviewLancet Infectious Diseases, The2016495
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal AdenocarcinomaCancer Cell2016442
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyLancet Oncology, The2016412
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLancet Oncology, The2016408
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityClinical Cancer Research2016397
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchNucleic Acids Research2016374
β-Lactams and β-Lactamase Inhibitors: An OverviewCold Spring Harbor Perspectives in Medicine2016358
Mitochondria are required for pro-ageing features of the senescent phenotypeEMBO Journal2016357
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of actionScience Translational Medicine2016343
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialLancet, The2016325
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic AttackNew England Journal of Medicine2016308
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialLancet Oncology, The2016296
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasisScience Translational Medicine2016291
Combenefit: an interactive platform for the analysis and visualization of drug combinationsBioinformatics2016286
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsCell2016274
Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl RadicalsJournal of the American Chemical Society2016269
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trialLancet Diabetes and Endocrinology,the2016249
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorNature2016238
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 studyLancet Infectious Diseases, The2016233